Noninvasive Detection of Response and Resistance in <i>EGFR</i> -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
2014 · Clinical Cancer Research · 772 citations
https://doi.org/10.1158/1078-0432.ccr-13-2482
G
Geoffrey R. Oxnard
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
993
Papers
28.8K
Citations
77
h-index
228
i10-index
Geoffrey R. Oxnard is an academic researcher from Eli Lilly (United States). The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Genomics and Diagnostics & Lung Cancer Research Studies. The author has an h-index of 77, co-authored 845 publications.
ORCID: 0000-0003-1054-8240Papers by this author
worksNew Targetable Oncogenes in Non–Small-Cell Lung Cancer
2013 · Journal of Clinical Oncology · 297 citations
https://doi.org/10.1200/jco.2012.42.9829
Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non–Small-Cell Lung Cancer
2015 · JAMA Oncology · 247 citations
https://doi.org/10.1001/jamaoncol.2015.4482
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC
2020 · Clinical Cancer Research · 210 citations
https://doi.org/10.1158/1078-0432.ccr-19-3608
Acquired <i>MET</i> D1228V Mutation and Resistance to MET Inhibition in Lung Cancer
2016 · Cancer Discovery · 170 citations
https://doi.org/10.1158/2159-8290.cd-16-0686
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium
2019 · Annals of Oncology · 154 citations
https://doi.org/10.1093/annonc/mdz046
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat